Pembrolizumab for T-Cell Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing pembrolizumab, a medication that boosts the immune system to fight cancer, in patients with Early-Stage NK/T-cell Lymphoma who haven't had chemotherapy yet. The goal is to see if pembrolizumab can shrink the cancer before any other treatments are given.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is pembrolizumab generally safe for humans?
Pembrolizumab, also known as Keytruda, has been shown to be generally safe in humans, but it can cause immune-related side effects like type 1 diabetes in rare cases (0.2%). Common side effects include fatigue, cough, nausea, and rash, while more serious immune-related reactions can affect organs like the lungs, liver, and thyroid.12345
What makes the drug pembrolizumab unique for treating T-cell lymphoma?
Pembrolizumab is unique because it works by blocking the PD-1 pathway, which helps the immune system attack cancer cells more effectively. This approach is different from traditional chemotherapy and has shown promising results in patients with relapsed or hard-to-treat T-cell lymphomas, offering a new option where few exist.12367
What data supports the effectiveness of the drug pembrolizumab for T-cell lymphoma?
Who Is on the Research Team?
Alison Moskowitz, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
Adults with early-stage NK/T-cell lymphoma, nasal type, who haven't had chemotherapy can join this trial. They must be generally healthy with good organ function and performance status. Women of childbearing age need a negative pregnancy test and agree to use contraception; men also have to agree to effective birth control or abstinence.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive pembrolizumab to test its effectiveness in shrinking Early-Stage NK/T-cell Lymphoma
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Pembrolizumab
Pembrolizumab is already approved in United States, European Union, United Kingdom for the following indications:
- Head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
- Melanoma
- Non-small cell lung cancer (NSCLC)
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Renal cell carcinoma
- Cervical cancer
- Endometrial carcinoma
- Head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
- Melanoma
- Non-small cell lung cancer (NSCLC)
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Renal cell carcinoma
- Cervical cancer
- Endometrial carcinoma
- Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor